BioMarin Pharmaceutical
BMRN
#1374
Rank
A$20.48 B
Marketcap
$107.49
Share price
-0.19%
Change (1 day)
-24.72%
Change (1 year)

P/E ratio for BioMarin Pharmaceutical (BMRN)

P/E ratio as of December 2024 (TTM): 85.9

According to BioMarin Pharmaceutical's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 85.8782. At the end of 2022 the company had a P/E ratio of 135.

P/E ratio history for BioMarin Pharmaceutical from 2001 to 2023

PE ratio at the end of each year

Year P/E ratio Change
2022135-153.34%
2021-252-1464.48%
202018.5-103.06%
2019-604204.98%
2018-19846.57%
2017-135540.95%
2016-21.1-78.27%
2015-97.0-2.36%
2014-99.380.75%
2013-55.06.12%
2012-51.8-26.19%
2011-70.2-621.08%
201013.5
200855.6-125.14%
2007-221372.47%
2006-46.8373.5%
2005-9.89350.39%
2004-2.20-65.19%
2003-6.3129.76%
2002-4.86-40.67%
2001-8.20

P/E ratio for similar companies or competitors

Company P/E ratio P/E ratio differencediff. Country
-4.24-104.94%๐Ÿ‡บ๐Ÿ‡ธ USA
-1.82-102.12%๐Ÿ‡บ๐Ÿ‡ธ USA
-0.8171-100.95%๐Ÿ‡บ๐Ÿ‡ธ USA
15.4-82.10%๐Ÿ‡ซ๐Ÿ‡ท France
-15.0-117.50%๐Ÿ‡บ๐Ÿ‡ธ USA
19.5-77.33%๐Ÿ‡บ๐Ÿ‡ธ USA

How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.